SCHEMBL1170030

SCHEMBL1170030

N=c1n(Cc2cc(F)cc(F)c2)c2ccccc2n1Cc1cc(F)cc(F)c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
TSHR P16473 3/20 0.50
SLC5A2 P31639 5/20 0.47
ALDH1A1 P00352 1/20 0.46
HTT P42858 3/20 0.45
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 1/20 0.41
IDO1 P14902 1/20 0.41
ALOX15 P16050 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HCRTR2 O43614 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
USP2 O75604 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1170132 0.83 LMNA (0.71) LMNASMN1; SMN2TSHRSLC5A2ALDH1A1
SCHEMBL1170704 0.79 LMNA (0.59) LMNASMN1; SMN2TSHRSLC5A2ALDH1A1
SCHEMBL1170484 0.78 LMNA (1.00) LMNASMN1; SMN2TSHRSLC5A2ALDH1A1
SCHEMBL1170639 0.73 SLC5A2 (0.78) LMNASMN1; SMN2TSHRSLC5A2ALDH1A1
SCHEMBL11716491 0.71 LMNA (0.70) LMNASMN1; SMN2TSHRSLC5A2ALDH1A1
SCHEMBL1170253 0.71 LMNA (0.65) LMNASMN1; SMN2TSHRSLC5A2ALDH1A1
SCHEMBL1169947 0.71 LMNA (0.59) LMNASMN1; SMN2TSHRSLC5A2ALDH1A1
SCHEMBL23241374 0.71 LMNA (0.54) LMNASMN1; SMN2TSHRSLC5A2ALDH1A1
SCHEMBL10353130 0.70 HTT (0.54) LMNASMN1; SMN2TSHRALDH1A1HTT
SCHEMBL2475227 0.69 LMNA (0.79) LMNASMN1; SMN2TSHRSLC5A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842817-B2 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2010-11-30 US claimed
EP-1838306-B1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH AS (DK) 2010-11-17 EP claimed
US-20080200529-A1 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels NEURO SEARCH A/S (DK) 2008-08-21 US claimed
EP-2319512-A1 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels. NeuroSearch AS (DK) 2011-05-11 EP disclosed
US-20110034527-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS SOERENSEN ULRIK SVANE 2011-02-10 US disclosed
US-7842817-B2 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2010-11-30 US disclosed
EP-1838306-B1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH AS (DK) 2010-11-17 EP disclosed
US-20100280087-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS SOERENSEN ULRIK SVANE 2010-11-04 US disclosed
US-20080200529-A1 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels NEURO SEARCH A/S (DK) 2008-08-21 US disclosed
EP-1838306-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2007-10-03 EP disclosed
WO-2006074991-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034527-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 LMNA 2521/4885SMN1; SMN2 2965/4885TSHR 4590/4885
US-20080200529-A1 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels KCNN2, KCNN1, KCNN3 LMNA 2521/4885SMN1; SMN2 2965/4885TSHR 4590/4885
US-20100280087-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 LMNA 2521/4885SMN1; SMN2 2965/4885TSHR 4590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.